<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916045</url>
  </required_header>
  <id_info>
    <org_study_id>07CC12</org_study_id>
    <secondary_id>REC - 07/H0808/193</secondary_id>
    <secondary_id>EudraCT - 2007-001657-26</secondary_id>
    <nct_id>NCT00916045</nct_id>
  </id_info>
  <brief_title>Pilot Study of Unrelated Cord Blood Transplantation</brief_title>
  <official_title>Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and feasibility of unrelated double and&#xD;
      single cord blood transplantation in patients with haematological malignancies using&#xD;
      reduced-intensity or myeloablative conditioning regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment issues&#xD;
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related mortality at day 100</measure>
    <time_frame>Day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival at one year post-transplant for each cohort</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>Days 14 (myeloblative conditioning only), 28, 56, 100 and months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutrophil engraftment by day 42</measure>
    <time_frame>Days 14, 28 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of platelet engraftment by 6 months</measure>
    <time_frame>Days 14, 28, 56, 100 and month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV and III-IV acute GVHD</measure>
    <time_frame>Days 28, 56, 100 and months 6, 9, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD during the first year</measure>
    <time_frame>Day 100 and months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year overall survival for each treatment cohort</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic infections</measure>
    <time_frame>Twice a week pre-transplant to day 100 then weekly or as clinically indicated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV, adenovirus and EBV activation</measure>
    <time_frame>Twice a week pre-transplant to day 100 then weekly or as clinically indicated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Days 14, 28, 56, 100 and months 6, 9, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of EBV infection and immunity following cord blood transplantation</measure>
    <time_frame>Days 14, 28, 56, 100 and months 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The development (if any) of transplant associated post transplant lymphoproliferative disease (PTLD)</measure>
    <time_frame>Days 14, 28, 56, 100 and months 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify any possible predictive markers for patients most at risk of PTLD development</measure>
    <time_frame>Days 14, 28, 56, 100 and months 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Pre-transplant and months 6, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of one year relapse or disease progression for each treatment cohort</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Lymphoblastic, Acute</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous busulphan</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
    <other_name>Busilvex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE INCLUSION CRITERIA:&#xD;
&#xD;
        In general this encompasses all haematological disorders where a volunteer unrelated donor&#xD;
        transplant is clinically indicated.&#xD;
&#xD;
          1. Acute, chronic leukaemia or myelodysplastic syndrome for which allogeneic&#xD;
             transplantation is considered as the best treatment option.&#xD;
&#xD;
               1. Acute myeloid leukaemia (AML) in first complete remission (CR1) with one of the&#xD;
                  following characteristics:&#xD;
&#xD;
                    -  High risk cytogenetic or molecular alterations (e.g. t(9;22), deletion&#xD;
                       7/7q-, monosomy 5 or del(5q), 3q26 alterations, complex karyotype [3 or more&#xD;
                       anomalies], p53 alterations, 11q23 especially t(6;11) abnormalities, FLT-3&#xD;
                       ITD)&#xD;
&#xD;
                    -  Leukocytes at diagnosis &gt; 50 x109/l (except in cases with good prognosis&#xD;
                       molecular rearrangements for which leukocytes should be &gt; 100 x 109/l)&#xD;
&#xD;
               2. Myelodysplastic syndromes&#xD;
&#xD;
                    -  International Prognosis Index (IPSS) above 1 (intermediate group 2 or high&#xD;
                       risk)&#xD;
&#xD;
                    -  IPSS 0 or 0.5 in the presence of cytopenias requiring treatment.&#xD;
&#xD;
               3. Therapy related AML or MDS in first CR&#xD;
&#xD;
               4. AML or MDS in second (CR2) or subsequent CR&#xD;
&#xD;
               5. Ph'-positive chronic myeloid leukaemia&#xD;
&#xD;
             i. In first chronic phase if refractory and/or intolerance to tyrosine kinase&#xD;
             inhibitors is clearly demonstrated ii. In second chronic phase&#xD;
&#xD;
          2. Acute lymphoblastic leukaemia (ALL)&#xD;
&#xD;
             a. In CR1 with one of the following characteristics: i. Very high risk chromosome or&#xD;
             molecular alterations (e.g. t(9;22), t(4;11), complex karyotype in adults, bcr/abl&#xD;
             rearrangements, MLL rearrangements) ii. Slow response to induction treatment defined&#xD;
             as the presence of &gt;10% blasts in bone marrow at day 14 of induction treatment iii.&#xD;
             Adults aged &gt; 30 years iv. Adults with B ALL cell line with a number of leukocytes at&#xD;
             diagnosis &gt;25 x 109/L or T ALL cell line with a number of leukocytes at diagnosis&#xD;
             &gt;100X109/L&#xD;
&#xD;
             b. In CR2 or subsequent CR&#xD;
&#xD;
          3. Non-Hodgkin's lymphoma&#xD;
&#xD;
               1. Follicular NHL: in second or subsequent complete or partial remission&#xD;
&#xD;
               2. Mantle cell NHL: in second or subsequent complete or partial remission&#xD;
&#xD;
               3. High grade NHL: in second complete or very good partial remission&#xD;
&#xD;
          4. Hodgkin's disease&#xD;
&#xD;
             a. in second or subsequent complete or partial remission&#xD;
&#xD;
          5. Chronic lymphocytic leukaemia.&#xD;
&#xD;
               1. in second or subsequent remission&#xD;
&#xD;
               2. with adverse risk prognostic features in first remission&#xD;
&#xD;
          6. Acquired bone marrow failure syndromes&#xD;
&#xD;
          7. Other haematological malignancies for which UD bone marrow transplantation is&#xD;
             indicated&#xD;
&#xD;
        PATIENT SELECTION&#xD;
&#xD;
        Inclusion criteria: myeloablative conditioning regimen&#xD;
&#xD;
          1. Aged under 35 years and greater than 18 years&#xD;
&#xD;
          2. Absence of HLA compatible related donor.&#xD;
&#xD;
          3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching&#xD;
             the international registries.&#xD;
&#xD;
          4. Patients with a HLA-compatible VUD but whose donor is considered by the&#xD;
             transplantation centre as unsuitable will also be eligible.&#xD;
&#xD;
          5. Availability of suitable UD-UCB unit/s.&#xD;
&#xD;
          6. Informed consent.&#xD;
&#xD;
        Exclusion criteria: myeloablative conditioning regimen&#xD;
&#xD;
          1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10&#xD;
             unrelated bone marrow donor&#xD;
&#xD;
          2. ECOG performance status worse than 2&#xD;
&#xD;
          3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF&#xD;
             less than 40%.&#xD;
&#xD;
          4. Hepatic disease, with total bilirubin above 20umol/l or AST &gt; 3 times upper limit of&#xD;
             normal.&#xD;
&#xD;
          5. Severe hypoxaemia, pO2 &lt; 70 mm Hg, with decreased DLCO &lt; 70% of predicted; or mild&#xD;
             hypoxemia, pO2 &lt; 80 mm Hg with severely decreased DLCO &lt; 60% of predicted.&#xD;
&#xD;
          6. Impaired renal function (creatinine &gt; 2 times upper limit of normal or creatinine&#xD;
             clearance &lt; 50% for age, gender, weight).&#xD;
&#xD;
          7. Patients who have received previous treatment with Thymoglobulin®&#xD;
&#xD;
          8. HIV or HTLV positive patients.&#xD;
&#xD;
          9. Female patients who are pregnant or breast feeding due to risks to foetus from&#xD;
             conditioning regimen and potential risks to nursing infants.&#xD;
&#xD;
         10. Life expectancy severely limited by diseases other than the disease indication for&#xD;
             transplant&#xD;
&#xD;
         11. Serious concurrent untreated infection e.g. active tuberculosis, mycoses or viral&#xD;
             infection&#xD;
&#xD;
         12. Serious psychiatric/ psychological disorders&#xD;
&#xD;
         13. Absence of /inability to provide informed consent&#xD;
&#xD;
         14. Serious diseases that prevent treatments with chemotherapy&#xD;
&#xD;
         15. Myelofibrosis&#xD;
&#xD;
        Inclusion criteria: reduced-intensity conditioning regimen (For both FluMel &amp; FluCyTBI&#xD;
        regimens):&#xD;
&#xD;
          1. Age under 70 years and older than 18 years&#xD;
&#xD;
          2. Absence of HLA compatible related donor.&#xD;
&#xD;
          3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching&#xD;
             the international registries.&#xD;
&#xD;
          4. Patients with a HLA-compatible VUD but whose donor is considered by the&#xD;
             transplantation centre as unsuitable will also be eligible.&#xD;
&#xD;
          5. Availability of suitable UD-UCB unit/s.&#xD;
&#xD;
          6. Informed consent.&#xD;
&#xD;
        Exclusion Criteria: reduced-intensity conditioning regimen (For both FluMel &amp; FluCyTBI&#xD;
        regimens):&#xD;
&#xD;
          1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10&#xD;
             unrelated bone marrow donor&#xD;
&#xD;
          2. ECOG performance status worse than 2&#xD;
&#xD;
          3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF&#xD;
             less than 35%.&#xD;
&#xD;
          4. Hepatic disease, with total bilirubin greater than 2 times upper limit of normal or&#xD;
             AST &gt; 5 times upper limit of normal.&#xD;
&#xD;
          5. Severe hypoxaemia, pO2 &lt; 70 mm Hg, with decreased DLCO &lt; 50% of predicted; or mild&#xD;
             hypoxemia, pO2 &lt; 80 mm Hg with severely decreased DLCO &lt; 50% of predicted.&#xD;
&#xD;
          6. Impaired renal function (creatinine &gt; 2 times upper limit of normal or creatinine&#xD;
             clearance &lt; 50% for age, gender, weight).&#xD;
&#xD;
          7. Previous irradiation that precludes the safe administration of an additional dose of&#xD;
             200 cGy of total body irradiation (TBI).&#xD;
&#xD;
          8. Patients who have received previous treatment with Thymoglobulin®&#xD;
&#xD;
          9. HIV or HTLV positive patients.&#xD;
&#xD;
         10. Female patients who are pregnant or breast feeding due to risks to foetus from&#xD;
             conditioning regimen and potential risks to nursing infants.&#xD;
&#xD;
         11. Life expectancy severely limited by diseases other than the disease indication for&#xD;
             transplant&#xD;
&#xD;
         12. Serious concurrent uncontrolled infection e.g. active tuberculosis, mycoses or viral&#xD;
             infection&#xD;
&#xD;
         13. Serious psychiatric/ psychological disorders&#xD;
&#xD;
         14. Absence of /inability to provide informed consent&#xD;
&#xD;
         15. Within 6 months of prior myeloablative transplant.&#xD;
&#xD;
         16. Patients with acute leukaemia in morphological relapse/ persistent/ progressive&#xD;
             disease&#xD;
&#xD;
         17. Intermediate or high grade NHL, mantle cell NHL and Hodgkin's disease that is&#xD;
             refractory or progressive on salvage therapy.&#xD;
&#xD;
         18. Myelofibrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pagliuca, MBBS, MA, FRCP, FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College Hosptial NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dr Antonio Pagliuca</name_title>
    <organization>King's College Hospital NHS Foundation Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

